Lopez-Galindo M,
Bagán JV. Apixaban and oral implications. J Clin Exp Dent. 2015;7(4):e528-34.
doi:10.4317/jced.52470
References
|
1. Lopes RD, Al-Khatib SM,
Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of
apixaban compared with warfarin according to patient risk of stroke and of
bleeding in atrial fibrillation: a secondary analysis of a randomised
controlled trial. The Lancet. 2012;380(9855):1749-58. PMid:23036896 |
|
|
|
|
|
2. Imberti D, Gallerani M,
Manfredini R. Therapeutic potential of apixaban in the prevention of venous
thromboembolism in patients undergoing total knee replacement surgery. J Thromb
Thrombolysis. 2012;34(2):208-13. |
|
|
|
|
|
3. Budovich A, Zargarova
O, Nogid A. Role of Apixaban (Eliquis) in the Treatment And Prevention of
Thromboembolic Disease. Pharm Ther. 2013;38(4):206-31. PMid:23785225 |
|
|
|
|
|
4. Frost C, Wang J, Nepal
S, Schuster A, Barrett YC, Mosqueda‐Garcia
R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety,
pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J
Clin Pharmacol. 2013;75(2):476-87. |
|
|
|
|
|
5. Maxwell BD, Tran SB,
Chen S, Zhang D, Chen B, Zhang H, et al. The syntheses and in vitro
biotransformation studies of [14C] apixaban, a highly potent, selective,
efficacious and orally bioavailable inhibitor of blood coagulation Factor Xa.
J
Labelled Compd Radiopharmaceut. 2011;54(8):418-25. |
|
|
|
|
|
6.
Briongos Figuero S, García Santos-Gallego C, Badimón JJ. Avances en el
tratamiento anticoagulante oral de la fibrilación auricular. Medicina Clínica. 2013;141(11):487-93. |
|
|
|
|
|
7. Wong PC, Pinto DJ,
Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable
factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478-92. |
|
|
|
|
|
8. Upreti VV, Wang J,
Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of extremes of body
weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of
apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6):908-16. |
|
|
|
|
|
9. Frost C, Nepal S, Wang
J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and
pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor,
in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776-86. |
|
|
|
|
|
10. Raghavan N, Frost CE,
Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and
pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81. |
|
|
|
|
|
11. Lassen M, Davidson B,
Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of
apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in
patients following total knee replacement1. Journal of Thrombosis and
Haemostasis. 2007;5(12):2368-75. |
|
|
|
|
|
12. Lopes RD, Alexander
JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction
in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE)
trial: design and rationale. Am Heart J. 2010;159(3):331-9. |
|
|
|
|
|
13.
Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC,
Sanz VV, et al. Reversal of Apixaban
Induced Alterations in Hemostasis by Different Coagulation Factor
Concentrates: Significance of Studies In Vitro with Circulating Human Blood.
PloS one. 2013;8(11):e78696. |
|
|
|
|
|
14. Mingarro-de-León A,
Chaveli-López B. Alternative to oral dicoumarin anticoagulants:
Considerations in dental care. J Clin Exp Dent. 2013;5(5):e273-8. |
|
|
|
|
|
15. Goldhaber SZ,
Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al. Apixaban versus
enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med.
2011;365(23):2167-77. |
|
|
|
|
|
16. Lassen MR, Gallus A,
Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for
thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487-98. |
|
|
|
|
|
17. Lassen MR, Raskob GE,
Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for
thromboprophylaxis after knee replacement (ADVANCE-2): a randomised
double-blind trial. The Lancet. 2010;375(9717):807-15. PMid:20206776 |
|
|
|
|
|
18. Roser-Jones C, Becker
RC. Apixaban: an emerging oral factor Xa inhibitor. J Thromb Thrombolysis.
2010;29(1):141-6. |
|
|
|
|
|
19. Connolly SJ, Eikelboom
J, Joyner C, Diener H, Hart R, Golitsyn S, et al. Apixaban in patients with
atrial fibrillation. N Engl J Med. 2011;364(9):806-17. |
|
|
|
|
|
20. Granger CB, Alexander
JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin
in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. |
|
|
|
|
|
21. Goldhaber SZ, Visani
L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the
International Cooperative Pulmonary Embolism Registry (ICOPER). The Lancet.
1999;353(9162):1386-9. PMid:10227218 |
|
|
|
|
|
22. Kakkar AK, Brenner B,
Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban
versus short-term enoxaparin for the prevention of venous thromboembolism
after total hip arthroplasty: a double-blind, randomised controlled trial.
The Lancet. 2008;372(9632):31-9. PMid:18582928 |
|
|
|
|
|
23. Geerts WH, Bergqvist
D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of Venous
ThromboembolismAmerican College of Chest Physicians Evidence-Based Clinical
Practice Guidelines. CHEST. 2008;133(6_suppl):381S-453S. PMid:18574271 |
|
|
|
|
|
24. Lassen MR, Raskob GE,
Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for
thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594-604. |
|
|
|
|
|
25. Agnelli G, Buller HR,
Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment
of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. |
|
|
|
|
|
26. Ogawa H, Goto S,
Matsuzaki M, Hiro S, Shima D, APPRAISE-J investigators. Randomized,
double-blind trial to evaluate the safety of apixaban with antiplatelet
therapy after acute coronary syndrome in Japanese patients (APPRAISE-J). Circ
J. 2013;77(9):2341-8. |
|
|
|
|
|
27. APPRAISE Steering
Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea
F, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in
combination with antiplatelet therapy after acute coronary syndrome: results
of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE)
trial. Circulation. 2009;119(22):2877-85. |
|
|
|
|
|
28. Alexander JH, Lopes
RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet
therapy after acute coronary syndrome. N Engl J Med 2011;365(8):699-708. |
|
|
|
|
|
29. Alexander JH, Lopes
RD, Thomas L, Alings M, Atar D, Aylward P, et al. Apixaban vs. warfarin with
concomitant aspirin in patients with atrial fibrillation: insights from the
ARISTOTLE trial. Eur Heart J. 2014;35(4):224-32. |
|
|
|
|
|
30. Garcia DA, Wallentin
L, Lopes RD, Thomas L, Alexander JH, Hylek EM, et al. Apixaban versus
warfarin in patients with atrial fibrillation according to prior warfarin
use: Results from the Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation trial. Am Heart J.
2013;166(3):549-58. |
|
|
|
|
|
31. Amin A, Stokes M, Wu
N, Gatt E, Makenbaeva D, Wiederkehr D, et al. Estimated medical cost reductions
associated with apixaban in real-world patients with non-valvular atrial
fibrillation. Journal of medical economics. 2013;16(10):1193-202. |
|
|
|
|
|
32. Hijazi Z, Wallentin L,
Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-Terminal
Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial
FibrillationInsights From the ARISTOTLE Trial (Apixaban for the Prevention of
Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol.
2013;61(22):2274-84. |
|
|
|
|
|
33. Eikelboom JW, Connolly
SJ, Gao P, Paolasso E, De Caterina R, Husted S, et al. Stroke risk and
efficacy of apixaban in atrial fibrillation patients with moderate chronic
kidney disease. Journal of Stroke and Cerebrovascular Diseases.
2012;21(6):429-35. PMid:22818021 |
|
|
|
|
|
34. Harrington AR,
Armstrong EP, Nolan PE,Jr, Malone DC. Cost-effectiveness of apixaban,
dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial
fibrillation. Stroke. 2013;44(6):1676-81. PMid:23549134 |
|
|
|
|
|
35. Miller CS, Grandi SM,
Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of
new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin
in patients with atrial fibrillation. Am J Cardiol. 2012;110(3):453-60. PMid: 22537354 |
|
|
|
|
|
36. Bahit MC, Lopes RD,
Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, et al. Apixaban in patients
with atrial fibrillation and prior coronary artery disease: insights from the
ARISTOTLE Trial. Int J Cardiol. 2013;170(2):215-20. PMid:24192334 |
|
|
|
|
|
37. Fakhri HR, Janket SJ,
Jackson EA, Baird AE, Dinnocenzo R, Meurman JH. Tutorial in oral
antithrombotic therapy: biology and dental implications. Med Oral Patol Oral
Cir Bucal. 2013;18(3):e461-72. |
|
|
|
|
|
38. Martin A, Le Bonniec
B, Fischer A, Marchand-Leroux C, Gaussem P, Samama C, et al. Evaluation of
recombinant activated factor VII, prothrombin complex concentrate, and
fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and
thrombosis. Int J Cardiol. 2013;168(4):4228-33. |
|
|
|
|
|
39. van Ryn J, Stangier J,
Haertter S, Liesenfeld K, Wienen W, Feuring M, et al. Dabigatran etexilate-a
novel, reversible, oral direct thrombin inhibitor: interpretation of
coagulation assays and reversal of anticoagulant activity. Thrombosis &
Haemostasis. 2010;103(6):1116-27. |
|
|
|
|
|
40. Spyropoulos AC,
Douketis JD. How I treat anticoagulated patients undergoing an elective
procedure or surgery. Blood. 2012;120(15):2954-62. PMid:20352166 |
|